B-Lab is a biotechnology venture originating from Konan University, engaged in the production and sales of β-1,3-1,6-glucan nanoparticles and betaine-derived aqueous solutions. Based on biomimetic chemistry, these products drive the development of next-generation, safe, and environmentally harmonized biomaterial technologies applicable to the food, cosmetic, pharmaceutical, agricultural, and chemical industries.
一般社団法人 超多様（設立準備中） (理事長 石戸 奈々子) はニューロダイバーシティへの理解を促し、ひとりひとりがそれぞれの場所で各々の「ちから」を発揮できる社会の構築するために、ニューロダイバーシティ...
[画像: https://prtimes.jp/i/126992/27/resize/d126992-27-2f4e433d623a8c40b92a-1.png ] B Lab（所長：石戸奈々子）は、ニューロダイバーシティプロジェクトの一環として、展示イベント「みんなの脳世界2026～...
[画像1: https://prtimes.jp/i/126992/24/resize/d126992-24-22ef53db8c2b806aaf47-0.jpg ] 表彰式の様子B Lab（所長：石戸奈々子）は、2025年11月3日に開催した「第2回ニューロダイバーシティアワード（Neurodiv...
[画像1: https://prtimes.jp/i/126992/23/resize/d126992-23-2812b1196360d9a160d1-2.png ] B Lab（所長 石戸奈々子）は、ともだちロボットプロジェクトの活動の一環として、イベント『ちょっと先のおもしろい未...
[画像1: https://prtimes.jp/i/126992/22/resize/d126992-22-ca2908bff491c349462c-2.png ] B Lab（所長 石戸奈々子）は、ニューロダイバーシティプロジェクトの活動の一環として、イベント『ちょっと先のおもし...
[画像: https://prtimes.jp/i/126992/20/resize/d126992-20-18020d1a22039683282b-0.png ] B Lab (所長 石戸奈々子) は、アートとテックで、ちょっと先のおしゃれを日常に届けるカルチャーデザインプロジェクト「...
[画像1: https://prtimes.jp/i/126992/19/resize/d126992-19-527ebed1e5678322732d-0.png ] B Lab (所長 石戸 奈々子) はニューロダイバーシティへの理解を促し、ひとりひとりがそれぞれの場所で各々の「ちから」...
[画像1: https://prtimes.jp/i/126992/17/resize/d126992-17-b66bb809cf4ac21dcbce-2.png ] B Lab（所長 石戸奈々子）は、ニューロダイバーシティプロジェクトの活動の一環として、 2025 年11 月2 日(日)・3 日(...
[画像: https://prtimes.jp/i/126992/16/resize/d126992-16-0b3a453db8ab49c0517a-0.png ] B Lab (所長 石戸奈々子) は、ニューロダイバーシティに関心のある全ての人が、学び合い、交流し、ニューロダイバーシテ...
[画像: https://prtimes.jp/i/126992/14/resize/d126992-14-ee5ec30a68ee14409545-0.png ] B Lab（所長 石戸奈々子）が主導する「超未来学」は、ニューロダイバーシティプロジェクト、Project Cybernetic being...
[画像: https://prtimes.jp/i/126992/15/resize/d126992-15-999e6e32330ab760fd75-1.png ] B Lab（iUの研究所、所長 石戸奈々子。以下、B Lab）は、ロボットと人間の関係性に新たな視点を提供し、技術的な革新だ...
[画像1: https://prtimes.jp/i/126992/13/resize/d126992-13-f7cb257b5c5a4ad5d342-2.png ] B Lab（所長 石戸奈々子）は、ニューロダイバーシティプロジェクトの活動の一環として、イベント『ちょっと先のおもし...
Some children suffer from learning disabilities and experience difficulties in daily life due to poor eye movement, which makes it difficult to read and to play sports. We are developing an evidence-based system that uses eye tracking and eye movement indexing technologies to assess eye movements and provide training for children who are encountering these eyesight challenges. We are currently deploying this system in municipal consultation centers, elementary schools, and after-school day care centers.
Solaris Bio revolutionizes regenerative medicine by integrating proprietary Animal-Origin-Free (AOF) formulation designs with advanced cell protection expertise. Centered on our "Organic Solvent-Free Cryopreservation Solution," which boasts the highest safety standards, we offer comprehensive cell manufacturing solutions, including world-class growth media. Leveraging innovative R&D and quality verified by the Certificate of Material Eligibility, we simultaneously enhance cell product efficacy and reduce costs, powerfully accelerating the social implementation of next-generation healthcare.
bacterico is a biotechnology startup developing personalized healthcare solutions based on an individual’s own gut microbiome. We isolate, select, and cultivate Bifidobacterium strains from stool samples and enhance them using proprietary culture methods to create personalized probiotic supplements optimized for each person’s gut environment. We also provide evidence-based programs tailored to key life moments, including Mama Flora, which supports maternal and infant health through prenatal gut microbiome care, and Preflora, a personalized nutrition and gut-health program designed specifically for individuals who are actively trying to conceive. Through science-driven, individualized interventions, bacterico aims to bring safe and effective microbiome-based solutions to everyday health.
The heart is an organ upon which life itself depends. With a commitment to providing new treatment options for heart failure and saving many lives, iHeart Japan is developing regenerative medicine products using iPS cells. Our product, IHJ-301, combines cells derived from iPS cells, including cardiomyocytes and endothelial cells, with a biomaterial, enabling long-term survival following implantation onto the heart and is expected to deliver strong therapeutic efficacy. Going forward, we plan to commercialize this product in Japan and internationally, with the aim of realizing a society in which patients can be saved without heart transplantation.